Nicotinamide Riboside May Reduce Airway Inflammation in COPD

A new study explores how boosting NAD+ levels could help manage chronic lung disease

Feb 14, 2025

∙ Paid

A professional medical illustration showing the potential benefits of nicotinamide riboside (NR) for reducing airway inflammation in COPD. The image features a clean and modern design with a transparent human torso highlighting the respiratory system. The lungs are shown with a subtle glow, emphasizing improved airway health. DNA strands float around the lungs, symbolizing NR's role in DNA repair and cellular health. Small inflammation markers around the bronchial tubes are visibly reduced in a before-and-after style comparison. The background is soft blue, giving a clinical and scientific feel, reinforcing the research-based findings.

Topline:

A randomized, placebo-controlled trial suggests that nicotinamide riboside (NR), an NAD+ precursor, may significantly reduce airway inflammation in patients with COPD, potentially improving disease management and reducing exacerbation risks.

Study Details

Chronic obstructive pulmonary disease (COPD) is a progressive respiratory condition that aff…

Keep reading with a 7-day free trial

Subscribe to Just Healthcare to keep reading this post and get 7 days of free access to the full post archives.